Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
The players are vying in the CD19 x CD20 Car-T arena.
The group’s point-of-care Car-T push looks to have stalled.
The group could soon provide clarity on CTX112’s regulatory path.
The company’s matching strategy for CB-010 will soon be put to the test.
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.